Position of the American Dietetic Association: Integration of medical nutrition therapy and pharmacotherapy

Journal of the American Dietetic Association

Volumn 103, Issue 10, 2003, Pages 1363-1370

  McCaffree, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CABERGOLINE; CANNABINOID RECEPTOR ANTAGONIST; CLOZAPINE; DIAZEPAM; FISH OIL; GARLIC OIL; GLUCAGON LIKE PEPTIDE 1; INSULIN; KAVA EXTRACT; LEVODOPA; METFORMIN; MIGLITOL; NATEGLINIDE; NEUROLEPTIC AGENT; PRAMLINTIDE; PSYCHOTROPIC AGENT; SERTRALINE; SIBUTRAMINE; SILYBUM MARIANUM EXTRACT; SULFONYLUREA; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; WARFARIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIET; DISORIENTATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; EPILEPSY; HEALTH CARE; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LETHARGY; LIVER TOXICITY; NUTRITION; OBESITY; PARKINSON DISEASE; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; WEIGHT GAIN; ALTERNATIVE MEDICINE; ARTICLE; CHRONIC DISEASE; DIET THERAPY; DIETETICS; DISEASE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; PATIENT CARE; PRACTICE GUIDELINE; UNITED STATES;

ALLIUM SATIVUM; PIPER METHYSTICUM; SILYBUM MARIANUM;

CHRONIC DISEASE; COMPLEMENTARY THERAPIES; DIABETES MELLITUS; DIETETICS; DISEASE MANAGEMENT; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; OBESITY; PATIENT CARE TEAM; QUALITY OF HEALTH CARE; SOCIETIES; UNITED STATES;

EID: 0242335917     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jada.2003.08.016     Document Type: Review

References (100)

1. Lacey K., Pritchett E. Nutrition Care Process and Model ADA adopts road map to quality care and outcomes management. J Am Diet Assoc. 103:2003;1061-1072
2. Carey M., Gillespie S. Position of the American Dietetic Association Cost effectiveness of medical nutrition therapy. J Am Diet Assoc. 95:1995;88-91
3. Chima C.S., Pollack H.A. Position of the American Dietetic Association Nutrition services in managed care. J Am Diet Assoc. 102:2002;1471-1478
4. Institute of Medicine Committee on Nutrition Services for Medicare Beneficiaries. The Role of Nutrition in Maintaining Health in the Nation's Elderly Evaluating Coverage of Nutrition Services for the Medicare Population. 1999;National Academy Press, Washington, DC
5. JNC VI- Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 157:1997;2413-2446
6. Kushner R. Teaming up to treat obesity. Nutr Clin Pract. 15:2002;3-4
7. Wesley J.R. Nutrition support teams Past, present and future. Nutr Clin Pract. 10:1995;219-228
8. Larson E. Disease management, registered dietitians, and medical nutrition therapy. J Am Diet Assoc. 102:2002;190-191
9. Ellrodt G., Cook D.J., Lee J., Cho M., Hunt D., Weingarten S. Evidence-based disease management. J Am Med Assoc. 278:1997;1687-1692
10. Wylie-Rosett J., Delahanty L. An integral role of the dietitian Implications of the Diabetes Prevention Program. J Am Diet Assoc. 102:2002;1065-1068
11. The American Dietetic Association. Position of the American Dietetic Association Nutrition services in managed care. J Am Diet Assoc. 102:2002;1471-1478
12. Ochs M. New Medicare changes to expand MNT access in 2002. J Am Diet Assoc. 102:2002;30
13. Fitzner K., Meyers E.F., Caputo N., Michael P. Are health plans changing their view on nutrition service coverage? J Am Diet Assoc. 103:2003;157-161
14. Sherwin R.S., Anderson R.M., Buse J.B., Chin M.H., Eddy D., Fradkin J., Ganiats T.G., Ginsberg H., Kahn R., Nwankwo R., Rewers M., Schlessinger L., Stern M., Vinicor F., Zinman B. The prevention or delay of type 2 diabetes. Diabetes Care. 26:2003;S62-S69
15. Pastors J.G., Warshaw H., Daly A., Franz M., Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 25:2002;608-613
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
17. Cheng J.W.M., Kalis M.M., Feifer S. Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy. 21:2001;828-841
18. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., Goff D.C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities A five-year naturalistic study. Am J Psychiatry. 157:2000;975-981
19. McIntyre R.S., McCann S.M., Kennedy S.H. Antipsychotic metabolic effects Weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 46:2001;273-281
20. Strowig S.M., Aviles-Santa M.L., Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care. 25:2002;1691-1698
21. Aronne L.J. Obesity as a disease Etiology, treatment, and management considerations for the obese patient. Obes Res. 10:2002;S95-S96
22. Aronne L.J. Classification of obesity and assessment of obesity-related health risks. Obes Res. 10:2002;105S-115S
23. Allison D.B., Casey M.D. Antipsychotic-induced weight gain A review of the literature. J Clin Psychiatry. 62:2001;22-31
24. Dezii C.M. Medication noncompliance What is the problem? Manage Care. 9:2000;7-12
25. Darmon N., Ferguson E.L., Briend A. A cost constraint alone has an adverse effect on food selection and nutrient density An analysis of human diets by linear programming. J Nutr. 132:2002;3764-3771
26. Goldman D.P., Smith J.P. Can patient self-management help explain the SES health gradient? Proc Natl Acad Sci U S A. 99:2002;100929-110934
27. Anderson J.V., Bybee D.I., Brown R.M., McLean D.F., Garcia E.M., Breer M.L., Schillo B.A. 5-a-day fruit and vegetable intervention improves consumption in a low-income population. J Am Diet Assoc. 101:2001;195-202
28. Krebs-Smith S.M., Kantor L.S. Choose a variety of fruits and vegetables daily understanding the complexities. J Nutr. 131:2001;487S-501S
29. Eisenberg D.M., Davis R.B., Ettner S.L., Appel S., Wilkey S., Van Rompay M., Kessler R.C. Trends in alternative medicine use in the United States, 1990-1997 Results of a follow-up national survey. JAMA. 280:1998;884-886
30. White House Commission on Complementary and Alternative Medicine Policy. Final Report White House Commission on complementary and alternative medicine policy. 2002;. Washington, DC
31. Fragakis A.S. The Health Professional's Guide to Popular Dietary Supplements. 2nd ed :2003;American Dietetic Association, Chicago, IL
32. The American Dietetic Association. Hyperlipidemia Medical Nutrition Therapy Protocol. American Dietetic Association Medical Nutrition Therapy Evidence Based Guides for Practice. 2001;American Dietetic Association, Chicago, IL
33. The American Dietetic Association. Nutrition Practice Guidelines for Gestational Diabetes Mellitus CD-ROM. 2002;American Dietetic Association, Chicago, IL
34. American Dietetic Association. Nutrition Practice Guidelines for Type I and Type 2 Diabetes Mellitus. American Dietetic Association Medical Nutrition Therapy Evidence-Based Guides for Practice. 2002;American Dietetic Association, Chicago, IL
35. American Dietetic Association. Chronic Kidney Disease (non-dialysis) Medical Nutrition Therapy Protocol. American Dietetic Association Medical Nutrition Therapy Evidence Based Guides for Practice. 2002;American Dietetic Association, Chicago, IL
36. Blumenthal M., Busse W.R., Goldberg A., Gruenwald J., Hall T., Riggins C.W., Rister R.S. The Complete German Commission E Monographs Therapeutic Guide to Herbal Medicines. 1998;American Botanical Council, Boston, MA
37. Blumenthal M., Goldberg A., Brinckmann J., Foster S. Herbal Medicine Expanded German Commission E Monographs. 2000;Integrative Medicine Communications, Newton, MA
38. Brinker F. Herb Contraindications and Drug Interactions. 1998;Eclectic Medical Publications, Sandy, OR
39. Physician's Desk Reference for Herbal Medicines. 2nd ed :2000;Medical Economics Company, Montvale, NJ
40. Physician's Desk Reference for Nonprescription Drugs and Dietary Supplements. 23rd ed :2002;Medical Economics Company, Montvale, NJ
41. Physician's Desk Reference for Nutritional Supplements. 2001;Medical Economics Company, Montvale, NJ
42. Blumenthal M. Interactions between herbs and conventional drugs Introductory considerations. HerbalGram. 49:2000;52-63
43. Physician's Desk Reference. 56th ed :2002;Medical Economics Company, Inc, Montvale, NJ
44. Kinsell K., Velkoff V.A. US Census Bureau, Series P95/01-1, An Aging World 2001. 2001;US Government Printing Office, Washington, DC
45. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 26:2003;S5-S20
46. Harris M.I., Flegal K.M., Cowie C.C., Eberhardt M.S., Goldstein D.E., Little R.R., Wiedmeyer H.M., Byrd-Holt D.D. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 21:1998;518-524
47. Mokdad A.H., Ford E.S., Bowman B.A., Nelson D.E., Engelgau M.M., Vinicor F., Marks J.S. Diabetes trends in the US 1990-1998. Diabetes Care. 23:2001;1278-1283
48. Boyle J.P., Honeycutt A.A., Narayan K.M., Hoerger T.J., Geiss L.S., Chen H., Thompson T.J. Projection of diabetes burden through 2050 Impact of changing demography and disease prevalence in the US. Diabetes Care. 24:2001;1936-1940
49. American Diabetes Association. Economic costs of diabetes in the United States in 2002. Diabetes Care. 26:2003;917-932
50. Hensrud D.D. Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes Res. 9:2001;S348-S353
51. Mokdad A.H., Ford E.S., Bowman B.A., Nelson D.E., Engelgau M.M., Vinicor F., Marks J.S. The continuing increase of diabetes in the US. Diabetes Care. 24:2001;412
52. Sinha R., Fisch G., Teague B., Tamborlane W.V., Banyas B., Allen K., Savoye M., Rieger V., Taksali S., Barbetta G., Sherwin R.S., Caprio S. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 346:2002;802-810
53. American Diabetes Association. Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care. 23:2000;381-389
54. Franz M.J., Bantle J.P., Beebe C.A., Brunzell J.D., Chiasson J.L., Garg A., Holzmeister L.A., Hoogwerf B., Mayer-Davis E., Mooradian A.D., Purnell J.Q., Wheeler M. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 25:2002;148-198
55. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 25:2002;202-212
56. American Diabetes Association. American Diabetes Association clinical practice recommendations 2002. Diabetes Care. 25:2002;S1-S147
57. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., Keinanen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., Salminen V., Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med. 344:2001;1343-1350
58. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med. 346:2002;393-403
59. Edelstein S.L., Knowler W.C., Bain R.P., Andres R., Barrett-Connor E.L., Dowse G.K., Haffner S.M., Pettitt D.J., Sorkin J.D., Muller D.C., Collins V.R., Hamman R.F. Predictors of progression from impaired glucose tolerance to NIDDM An analysis of six prospective studies. Diabetes. 46:1997;701-710
60. The University of Wisconsin Medical School and Boron LePore Group Companies. Management of Drug-Induced Weight Gain, A Continuing Education Monograph for Physicians. 2002;Pub-Medical Education Systems, Inc, Philadelphia, PA
61. Rosenthal J.H., Mauersberger H. Effects on blood pressure of the α glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest. 22:2002;695-701
62. Wolever T.M., Chiasson J.L., Josse R.G., Hunt J.A., Palmason C., Rodger N.W., Ross S.A., Ryan E.A., Tan M.H. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30%-60% of energy from carbohydrate. Diabetes Care. 21:1998;1612-1618
63. Blonde L. Management of type 2 diabetes Update on new pharmacological options. Manage Care. 9:2000;11-17
64. Ahren B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., Sandqvist M., Bavenholm P., Efendic S., Eriksson J.W., Dickinson S., Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 25:2001;869-875
65. Samsom M., Szarka L.A., Camilleri M., Vella A., Zinsmeister A.R., Rizza R.A. Pramlintide, an amylin analog, selectively delays gastric emptying Potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol. 278:2000;G946-G951
66. Delgado-Aros S., Kim D.Y., Burton D.D., Thomforde G.M., Stephens D., Brinkmann B.H., Vella A., Camilleri M. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 282:2002;G424-G431
67. Moran L.J., Noakes M., Clifton P.M., Tomlinson L., Norman R.J. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 88:2003;812-819
68. Franks S. Polycystic ovary syndrome. N Eng J Med. 333:1995;853-861
69. Van den Berghe G., Wouters P.J., Bouillon R., Weekers F., Verwaest C., Schetz M., Vlasselaers D., Ferdinande P., Lauwers P. Outcome benefit of intensive insulin therapy in the critically ill Insulin dose versus glycemic control. Crit Care Med. 31:2003;359-366
70. Ven den Berghe G., Wouters P.J., Weekers F., Verwaest C., Bruyninckx F., Schetz M., Vlasselaers D., Ferdinande P., Lauwers P., Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 345:2001;1359-1367
71. Pi-Sunyer F.X. The obesity epidemic Pathophysiology and consequences of obesity. Obes Res. 10:2002;97S-104S
72. Hill J.O., Wyatt H. Outpatient management of obesity A primary care perspective. Obes Res. 10:2002;124S-130S
73. Jackson Y., Dietz W.H., Sanders C., Kolbe L.J., Whyte J.J., Wechsler H., Schneider B.S., McNally L.A., Charles-Azure J., Vogel-Taylor M., Starke-Reed P., Hubbard V.S., Johnson-Taylor W.L., Troiano R.P., Donato K., Yanovski S., Kuczmarski R.J., Haverkos L., McMurry K., Wykoff R.F., Woo V., Noonan A.S., Rowe J., McCarty K., Spain C.B. Summary of the 2000 Surgeon General's listening session Toward a national action plan on overweight and obesity. Obes Res. 10:2002;1299-1305
74. McCrory M.A., Suen V.M., Roberts S.B. Biobehavioral influences on energy intake and adult weight gain. J Nutr. 132:2002;3830S-3834S
75. US Department of Health and Human Services, National Center for Health Statistics. Prevalence of Overweight and Obesity among Adults United States, 1999. 1999;Centers for Disease Control and Prevention, Atlanta, GA
76. Roberts S.B., Williamson D.F. Causes of adult weight gain. J Nutr. 132:2002;3824S-3825S
77. Jakicic J.M. The role of physical activity in prevention and treatment of body weight gain in adults. J Nutr. 132:2002;3826S-3829S
78. Kennedy E.T., Bowman S.A., Spence J.T., Freedman M., King J. Popular diets Correlation to health, nutrition, and obesity. J Am Diet Assoc. 101:2001;411-420
79. Nestle M. Increasing portion sizes in American diets More calories, more obesity. J Am Diet Assoc. 103:2003;39-40
80. Smiciklas-Wright H., Mitchell D.C., Mickle S.J., Goldman J.D., Cook A. Foods commonly eaten in the United States, 1989-1991 and 1994-1996 Are portion sizes changing? J Am Diet Assoc. 103:2003;41-47
81. Farrigan C., Pang K. Obesity market overview. Nat Rev Drug Discov. 1:2002;257-258
82. Yanovski S.Z., Yanovski J.A. Obesity. N Engl J Med. 346:2002;591-602
83. Fujioka K. Management of obesity as a chronic disease Nonpharmacologic, pharmacologic, and surgical options. Obes Res. 10:2002;116S-123S
84. Bray G.A., Greenway F.L. Current and potential drugs for treatment of obesity. Endocr Rev. 20:1999;805-875
85. Hansen D.L., Toubro S., Stock M.J., Macdonald I.A., Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr. 68:1998;1180-1186
86. Hansen D.L., Toubro S., Stock M.J., Macdonald I.A., Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord. 23:1999;1016-1024
87. FAQ on OTC Medications and supplements. Available at: www.weightloss-news.com. Accessed January 30, 2003.
88. Annual Drugs in Development Issue, Part III. Compounds no longer under development. Available at: www.weightloss-news.com. Accessed January 30, 2003.
89. Annual Drugs in Development Report, Part II. Pipeline Drugs. Available at: www.weightloss-news.com. Accessed January 30, 2003.
90. Appel L.J. Nonpharmacologic therapies that reduce blood pressure A fresh perspective. Clin Cardiol. 22:1999;III-1-III-5
91. Singer G.M., Izhar M., Black H.R. Goal-oriented hypertension management Translating clinical trials into practice. Hypertension. 40:2002;464-469
92. Harsha D.W., Lin P.H., Obarzanek E., Karanja N.M., Moore T.J., Caballero B. Dietary approaches to stop hypertension A summary of study results. J Am Diet Assoc. 99:1999;S35-S39
93. JNC V- Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 153:1993;154-183
94. Graudal N.A., Galloe A.M., Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride A meta-analysis. J Am Med Assoc. 279:1998;1383-1391
95. Staessen J., Fagard R., Lijnen P., Amery A. Body weight, sodium intake, and blood pressure. J Hypertens. 7:1989;S19-S23
96. American Heart Association. 2002 Heart and Stroke Statistical Update. 2002;American Heart Association, Dallas, TX
97. Sikand G., Kashyap M.L., Yang I. Medical Nutrition Therapy lowers serum cholesterol and saves medication costs in men with hypercholesterolemia. J Am Diet Assoc. 98:1998;889-894
98. Sikand G., Kashyap M.L., Wong N.D., Hsu J.C. Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance. J Am Diet Assoc. 100:2000;218-224
99. Delahanty L.M., Sonnenberg L.M., Hayden D., Nathan D.M. Clinical and cost outcomes of Medical Nutrition Therapy for hypercholesterolemia A controlled trial. J Am Diet Assoc. 101:2001;1012-1016. 1021-1023
100. Clemmer K.F., Binkoski A.E., Coval S.M., Zhao G., Kris-Etherton P.M. Diet and drug therapy A dynamic duo for reducing coronary heart disease risk. Curr Atheroscler Rep. 3:2001;507-513